Bayer Statement on the new ACC / AHA 2019 Directive on Primary Prevention of Cardiovascular Diseases



[ad_1]

WHIPPANY, N.J., March 17, 2019 / PRNewswire / – No one should start, stop, or change an aspirin treatment without talking to their health care provider first. With recent changes made to cardiovascular guidelines by the American College of Cardiology (ACC) and the American Heart Association (AHA), Bayer realizes that there may be confusion as to the ## 147 ## 39, appropriate use of aspirin.

It is important to note that the changes made to the ACC and AHA guidelines offer more specific criteria with respect to the proper use of aspirin in individuals. Having never experienced a cardiac event (primary prevention). The updated guidelines do not change the recommendations of aspirin in secondary prevention and demonstrate that aspirin still has a role to play in primary prevention.

Aspirin remains the basic treatment for the prevention of secondary cardiovascular events (secondary prevention). For those who have ever suffered a heart attack, stroke, or other cardiovascular event, stopping treatment with aspirin without the help of a doctor can increase by 63% the risk of another heart attack and 40% a stroke. The guidelines do not alter the role of aspirin during an alleged heart attack, as indicated by a doctor.

Aspirin is widely recognized as one of the best antiplatelet therapies among a wide range of cardiovascular risks because of its proven efficacy, safety and cost-effectiveness.

Find more information on www.bayeraspirin.com.

Contact
Dan Childs, Director, US External Communications
Cell: 973.437.0809
Email: [email protected]

SOURCE Bayer

Related Links

http://www.bayer.us

[ad_2]
Source link